Trastuzumab deruxtecan
daiichi Sankyo,astrazeneca
['biomarker', 'destiny,breast,4', 'breast', 'destiny,breast,2', 't-dxd', 'destiny,breast,3', 'destiny,breast04']
shanu modi will present destiny-breast04 biomarker analysis in patients with her2-low, hr+ metastatic #breastcancer at #asco23. last year, the fda approved t-dxd for people with this type of breast cancer based on the trial led by dr. modi. 
The official account of @MSKCancerCenter’s Department of Medicine. Chair/Dept. Head: @debschrag